3D microtumors in vitro supported by perfused vascular networks

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Sobrino, Agua ^a   Phan, Duc T T ^a   Datta, Rupsa ^a   Wang, Xiaolin ^a   Hachey, Stephanie J ^a   Romero López, Mónica ^a   Gratton, Enrico ^a   Lee, Abraham P ^a   George, Steven C ^b   Hughes, Christopher C W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

BIOLOGICAL MODEL; BREAST TUMOR; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; MCF-7 CELL LINE; METABOLISM; MICROFLUIDIC ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MCF-7 CELLS; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84983543822     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31589     Document Type: Article

References (58)

1. Paul, S. M. et al. How to improve R and D productivity: the pharmaceutical industrys grand challenge. Nat Rev Drug Discov 9, 203-214, doi: 10.1038/nrd3078 (2010).
2. Chitcholtan, K., Asselin, E., Parent, S., Sykes, P. H. and Evans, J. J. Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Exp Cell Res 319, 75-87, doi:10.1016/j.yexcr.2012.09.012 (2013).
3. Kenny, P. A. and Bissell, M. J. Tumor reversion: correction of malignant behavior by microenvironmental cues. International journal of cancer. Journal international du cancer 107, 688-695, doi:10.1002/ijc.11491 (2003).
4. Yamada, K. M. and Cukierman, E. Modeling tissue morphogenesis and cancer in 3D. Cell 130, 601-610, doi:10.1016/j.cell.2007.08.006 (2007).
5. Santini, M. T. et al. MG-63 human osteosarcoma cells grown in monolayer and as three-dimensional tumor spheroids present a different metabolic profile: a (1)H NMR study. FEBS Lett 557, 148-154 (2004).
6. Wrzesinski, K. et al. The cultural divide: exponential growth in classical 2D and metabolic equilibrium in 3D environments. Plos One 9, e106973, doi:10.1371/journal.pone.0106973 (2014).
7. Levinger, I., Ventura, Y. and Vago, R. Life is three dimensional-as in vitro cancer cultures should be. Adv Cancer Res 121, 383-414, doi:10.1016/B978-0-12-800249-0.00009-3 (2014).
8. Siolas, D. and Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73, 5315-5319, doi:10.1158/0008-5472.CAN-13-1069 (2013).
9. Heylman, C., Sobrino, A., Shirure, V. S., Hughes, C. C. and George, S. C. A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. Experimental biology and medicine, doi:10.1177/1535370214525295 (2014).
10. Hsu, Y. H. et al. Full range physiological mass transport control in 3D tissue cultures. Lab on a chip 13, 81-89, doi:10.1039/ c2lc40787f (2013).
11. Hsu, Y. H., Moya, M. L., Hughes, C. C., George, S. C. and Lee, A. P. A microfluidic platform for generating large-scale nearly identical human microphysiological vascularized tissue arrays. Lab on a chip 13, 2990-2998, doi:10.1039/c3lc50424g (2013).
12. Moya, M. L., Hsu, Y. H., Lee, A. P., Hughes, C. C. and George, S. C. In vitro perfused human capillary networks. Tissue engineering. Part C, Methods 19, 730-737, doi:10.1089/ten.TEC.2012.0430 (2013).
13. Stringari, C. et al. Phasor approach to fluorescence lifetime microscopy distinguishes different metabolic states of germ cells in a live tissue. Proc Natl Acad Sci USA 108, 13582-13587, doi:10.1073/pnas.1108161108 (2011).
14. Yuan, W., Lv, Y., Zeng, M. and Fu, B. M. Non-invasive measurement of solute permeability in cerebral microvessels of the rat. Microvasc Res 77, 166-173, doi:10.1016/j.mvr.2008.08.004 (2009).
15. Nakatsu, M. N. and Hughes, C. C. An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods in enzymology 443, 65-82, doi:10.1016/S0076-6879(08)02004-1 (2008).
16. Newman, A. C., Nakatsu, M. N., Chou, W., Gershon, P. D. and Hughes, C. C. The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. Mol Biol Cell 22, 3791-3800, doi:10.1091/mbc. E11-05-0393 (2011).
17. Berthod, F., Symes, J., Tremblay, N., Medin, J. A. and Auger, F. A. Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. J Cell Physiol 227, 2130-2137, doi:10.1002/jcp.22943 (2012).
18. Lin, S. L., Kisseleva, T., Brenner, D. A. and Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagenproducing cells in obstructive fibrosis of the kidney. Am J Pathol 173, 1617-1627, doi:10.2353/ajpath.2008.080433 (2008).
19. Sacharidou, A. et al. Endothelial lumen signaling complexes control 3D matrix-specific tubulogenesis through interdependent Cdc42- and MT1-MMP-mediated events. Blood 115, 5259-5269, doi:10.1182/blood-2009-11-252692 (2010).
20. Hanahan, D. and Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
21. Ostuni, E., Chen, C. S., Ingber, D. E. and Whitesides, G. M. Deposition of proteins and cells in arrays of microwells. Langmuir 17, 2828-2834 (2001).
22. Toepke, M. W. and Beebe, D. J. PDMS absorption of small molecules and consequences in microfluidic applications. Lab on a chip 6, 1484-1486, doi:10.1039/b612140c (2006).
23. Reese, J. M. et al. ERbeta1: characterization, prognosis, and evaluation of treatment strategies in ERalpha-positive and -negative breast cancer. BMC Cancer 14, 749, doi:10.1186/1471-2407-14-749 (2014).
24. Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370, 734-743, doi:10.1056/ NEJMoa1309748 (2014).
25. Arrillaga-Romany, I., Reardon, D. A. and Wen, P. Y. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs 23, 199-210, doi:10.1517/13543784.2014.856880 (2014).
26. Ferrarotto, R. and Hoff, P. M. Antiangiogenic drugs for colorectal cancer: exploring new possibilities. Clin Colorectal Cancer 12, 1-7, doi:10.1016/j.clcc.2012.06.002 (2013).
27. Bagley, R. G. et al. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 63, 5866-5873 (2003).
28. Awada, A. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92, 1855-1861, doi:10.1038/sj.bjc.6602584 (2005).
29. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L. and Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27, 482-487 (1991).
30. Albert, D. H. et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5, 995-1006, doi:10.1158/1535-7163.MCT-05-0410 (2006).
31. Heikal, A. A. Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies. Biomark Med 4, 241-263, doi:10.2217/bmm.10.1 (2010).
32. Zhao, Y., Butler, E. B. and Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4, e532, doi:10.1038/ cddis.2013.60 (2013).
33. Pate, K. T. et al. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J 33, 1454-1473, doi:10.15252/embj.201488598 (2014).
34. Skala, M. C. et al. In vivo multiphoton fluorescence lifetime imaging of protein-bound and free nicotinamide adenine dinucleotide in normal and precancerous epithelia. J Biomed Opt 12, 024014, doi:10.1117/1.2717503 (2007).
35. Bird, D. K. et al. Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res 65, 8766-8773, doi:10.1158/0008-5472.CAN-04-3922 (2005).
36. Harjes, U., Bensaad, K. and Harris, A. L. Endothelial cell metabolism and implications for cancer therapy. Br J Cancer 107, 1207-1212, doi:10.1038/bjc.2012.398 (2012).
37. Peters, K. et al. Changes in human endothelial cell energy metabolic capacities during in vitro cultivation. The role of "aerobic glycolysis" and proliferation. Cell Physiol Biochem 24, 483-492, doi:10.1159/000257490 (2009).
38. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956).
39. Sengupta, D. and Pratx, G. Imaging metabolic heterogeneity in cancer. Mol Cancer 15, 4, doi:10.1186/s12943-015-0481-3 (2016).
40. Wang, H. W. et al. Differentiation of apoptosis from necrosis by dynamic changes of reduced nicotinamide adenine dinucleotide fluorescence lifetime in live cells. J Biomed Opt 13, 054011, doi:10.1117/1.2975831 (2008).
41. Miller, J. S. et al. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater 11, 768-774, doi:10.1038/nmat3357 (2012).
42. Zheng, Y. et al. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci USA 109, 9342-9347, doi:10.1073/pnas.1201240109 (2012).
43. Aljitawi, O. S. et al. A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells. Leuk Lymphoma 55, 378-391, doi:10.3109/10428194.2013.793323 (2014).
44. Longati, P. et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 13, 95, doi:10.1186/1471-2407-13-95 (2013).
45. Perche, F. and Torchilin, V. P. Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol Ther 13, 1205-1213, doi:10.4161/cbt.21353 (2012).
46. Adams, W. J. et al. Functional vascular endothelium derived from human induced pluripotent stem cells. Stem Cell Reports 1, 105-113, doi:10.1016/j.stemcr.2013.06.007 (2013).
47. Hewitt, K. J. et al. Epigenetic and phenotypic profile of fibroblasts derived from induced pluripotent stem cells. Plos One 6, e17128, doi:10.1371/journal.pone.0017128 (2011).
48. Sui, X. et al. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep 4, 4694, doi:10.1038/srep04694 (2014).
49. Ferrara, N. and Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974, doi:10.1038/nature04483 (2005).
50. Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427 (2004).
51. Chimote, G. et al. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational antiangiogenic drug discovery. Drug Des Devel Ther 8, 1107-1123, doi:10.2147/DDDT.S55621 (2014).
52. Bost, F., Decoux-Poullot, A. G., Tanti, J. F. and Clavel, S. Energy disruptors: rising stars in anticancer therapy? Oncogenesis 5, e188, doi:10.1038/oncsis.2015.46 (2016).
53. Ganapathy-Kanniappan, S. and Geschwind, J. F. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 12, 152, doi:10.1186/1476-4598-12-152 (2013).
54. Pavlova, N. N. and Thompson, C. B. The Emerging Hallmarks of Cancer Metabolism. Cell metabolism 23, 27-47, doi:10.1016/j. cmet.2015.12.006 (2016).
55. Seaman, M. E., Peirce, S. M. and Kelly, K. Rapid analysis of vessel elements (RAVE): a tool for studying physiologic, pathologic and tumor angiogenesis. PLoS One 6, e20807, doi:10.1371/journal.pone.0020807 (2011).
56. Jeon, J. S. et al. Generation of 3D functional microvascular networks with human mesenchymal stem cells in microfluidic systems. Integrative biology: quantitative biosciences from nano to macro 6, 555-563, doi:10.1039/c3ib40267c (2014).
57. Crosignani, V., Jahid, S., Dvornikov, A. S. and Gratton, E. A deep tissue fluorescence imaging system with enhanced SHG detection capabilities. Microsc Res Tech 77, 368-373, doi:10.1002/jemt.22354 (2014).
58. Digman, M. A., Caiolfa, V. R., Zamai, M. and Gratton, E. The phasor approach to fluorescence lifetime imaging analysis. Biophys J 94, L14-16, doi:10.1529/biophysj.107.120154 (2008).